Loading…
Co-Diagnostics, Inc. is projected to rise to $2.07 by 2027, a +40% move from its current price of $1.48. CODX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.35 | $1.48 | $1.63 | +0.08% |
| Aug 6 | $1.30 | $1.48 | $1.69 | +0.16% |
| Aug 7 | $1.26 | $1.48 | $1.74 | +0.23% |
| Aug 8 | $1.23 | $1.48 | $1.79 | +0.31% |
| Aug 9 | $1.21 | $1.49 | $1.83 | +0.39% |
| Aug 10 | $1.18 | $1.49 | $1.87 | +0.47% |
| Aug 11 | $1.16 | $1.49 | $1.91 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.16 | $1.49 | $1.91 | +0.55% |
| Week 2 | $1.05 | $1.50 | $2.12 | +1.10% |
| Week 3 | $0.9803 | $1.50 | $2.31 | +1.65% |
| Week 4 | $0.9224 | $1.51 | $2.48 | +2.20% |
| Week 5 | $0.8749 | $1.52 | $2.64 | +2.76% |
| Week 6 | $0.8344 | $1.53 | $2.80 | +3.32% |
| Week 7 | $0.7992 | $1.54 | $2.96 | +3.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc.
was incorporated in 2013 and is based in Salt Lake City, Utah.
Co-Diagnostics, Inc. (CODX) trades at $1.51 per share and has a market cap of $5.52M. It is ranked 5256 in market capitalization among listed assets. The current price and market positioning place CODX in a highly small-cap tier within the healthcare sector.
The forecast presents a path of rising average prices from 2026 onward, with 2026 avg $1.51, 2027 avg $2.13, 2028 avg $2.44, 2029 avg $2.11, 2030 avg $2.16, 2033 avg $2.90, 2034 avg $2.77, 2035 avg $2.58, 2040 avg $3.66, and 2050 avg $4.38. This tilt toward higher mid-to-long-term averages suggests potential upside across several future years.
A major floor 13.2% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 141.2% above — a clean break opens room to run.
A major ceiling 656.1% above — clearing it would confirm fresh momentum.
Key CODX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CODX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.59 | Sell | $1.62 | Sell |
| MA 10 | $1.93 | Sell | $1.86 | Sell |
| MA 20 | $2.26 | Sell | $2.25 | Sell |
| MA 50 | $3.75 | Sell | $2.82 | Sell |
| MA 100 | $2.81 | Sell | $3.31 | Sell |
| MA 200 | $5.06 | Sell | $5.19 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.10 | Buy |
| Stoch RSI (14) | 18.90 | Buy |
| CCI (20) | -153.45 | Sell |
| Williams %R (14) | -97.41 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -42.17 | Sell |
| Bollinger %B (20,2) | 0.02 | Neutral |
| Stochastic %K (14) | 2.59 | Buy |
| TRIX (15) | -2.13 | Sell |
| Awesome (5,34) | -1.12 | Sell |
| Ultimate (7,14,28) | 13.76 | Buy |
| Momentum (10) | -1.02 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 1.30 | Buy |
| ADX (14) | 27.41 | Sell |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 30, indicating limited upside momentum near-term. The SMA50 is $3.76 and the SMA200 is $5.16, framing resistance and longer-term trend boundaries. Support is at $1.41 and resistance at $3.84, with a 30-day trading range from $0.7922 to $2.88.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.28 | $1.48 | $1.93 | 0% | Neutral | |
| $1.51 | $2.07 | $3.07 | +40% | Bullish | |
| $1.64 | $2.40 | $3.80 | +62% | Bullish | |
| $1.34 | $2.06 | $3.43 | +39% | Bullish | |
| $1.31 | $2.11 | $3.66 | +43% | Bullish | |
| $1.03 | $1.73 | $3.10 | +17% | Neutral | |
| $0.9817 | $1.73 | $3.19 | +17% | Neutral | |
| $1.54 | $2.82 | $5.35 | +90% | Bullish | |
| $1.44 | $2.75 | $5.36 | +86% | Bullish | |
| $1.27 | $2.52 | $5.03 | +71% | Bullish | |
| $1.63 | $3.62 | $7.94 | +145% | Bullish | |
| $1.91 | $4.25 | $9.77 | +187% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.28 | $1.48 | $1.73 | +0.00% |
| September 2026 | $1.21 | $1.47 | $1.87 | -0.49% |
| October 2026 | $1.29 | $1.59 | $2.06 | +7.89% |
| November 2026 | $1.22 | $1.51 | $1.99 | -4.66% |
| December 2026 | $1.15 | $1.44 | $1.93 | -4.74% |
Click any year to see its month-by-month CODX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CODX could reach as high as $1.93, with a base case around $1.48 and support toward $1.28 — roughly 0% from $1.48. A consolidation phase looks the most probable path here.
Expect CODX to range from $1.51 to $3.07 through 2027. The $2.07 average target implies a +40% move from current prices. That is up +40% on the projected 2026 average. Momentum favours further upside here.
The CODX price prediction for 2028 points to an average of $2.40 (low $1.64, high $3.80) — a potential gain of +62% on today's $1.48. Buyers look set to stay in control over this stretch.
In 2029, CODX is projected to trade between $1.34 and $3.43, averaging $2.06 — a potential gain of +39% from today's $1.48. That is -14% versus the projected 2028 average. Momentum favours further upside here.
Co-Diagnostics, Inc.'s 2030 outlook centres on $2.11, within a $1.31 to $3.66 range. That is up +3% on the projected 2029 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, CODX could reach as high as $3.10, with a base case around $1.73 and support toward $1.03 — roughly +17% from $1.48. Price action looks broadly range-bound.
Expect CODX to range from $0.9817 to $3.19 through 2032. The $1.73 average target implies a +17% move from current prices. That is 0% versus the projected 2031 average. A consolidation phase looks the most probable path here.
The CODX price prediction for 2033 points to an average of $2.82 (low $1.54, high $5.35) — a potential gain of +90% on today's $1.48. Momentum favours further upside here.
In 2034, CODX is projected to trade between $1.44 and $5.36, averaging $2.75 — a potential gain of +86% from today's $1.48. That is -2% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Co-Diagnostics, Inc.'s 2035 outlook centres on $2.52, within a $1.27 to $5.03 range. That is -8% versus the projected 2034 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2040, CODX could reach as high as $7.94, with a base case around $3.62 and support toward $1.63 — roughly +145% from $1.48. Buyers look set to stay in control over this stretch.
Expect CODX to range from $1.91 to $9.77 through 2050. The $4.25 average target implies a +187% move from current prices. That is up +17% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CODX today (≈ 675.675676 CODX) could be worth
$2,868.86
+$1,868.86 (+187%) by 2050 · US Dollar
Based on the average projected CODX price of $4.25 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CODXwould be worth at today's price.
$1,000 invested in CODX on Jul 31, 2025 (≈ 128.700129 CODX) would be worth
$190.48
-$809.52 (-81.0%) today · 0.19× · US Dollar
Based on a CODX entry price of $7.77 vs. today's $1.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.1 | $704.76 | -29.5% |
| 1 month ago | $3.08 | $480.52 | -51.9% |
| 3 months ago | $1.55 | $954.84 | -4.5% |
| 6 months ago | $2.42 | $611.57 | -38.8% |
| 1 year ago | $7.77 | $190.48 | -81.0% |
| All time (5.0y) ago | $308.4 | $4.8 | -99.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CODX forecast.
Our base-case forecast reaches $3.00 around 2040.
Implied market cap at $3.00: $10.97M
The multi-year forecast shows a gradual lift in expected prices with notable upside in several years. For 2027 the avg is $2.13 with ROI 40.9% and a BULLISH sentiment, followed by 2028 avg $2.44 (ROI 61.3%) and 2029 avg $2.11 (ROI 39.8%). In 2030 the avg is $2.16 with ROI 42.7% and a BULLISH stance, while 2031 and 2032 show more modest gains (avg $1.74 and $1.78; ROI 15.5% and 18.1%, respectively).
The forecast turns increasingly bullish in 2033 with avg $2.90 and ROI 91.8%, then 2034 avg $2.77 (ROI 83.7%) and 2035 avg $2.58 (ROI 70.8%). Longer term, 2040 is expected to average $3.66 with ROI 142.5% and 2050 is expected to average $4.38 with ROI 190.2%, both labeled BULLISH. These figures reflect upside potential across a number of years, tempered by higher volatility and the inherent uncertainty in price forecasts.
The asset also shows high historical volatility (annualized Volatility 200%), underscoring the risk that outcomes may diverge from the projected paths.
Tap a question to reveal the answer.
min $1.34, avg $2.16, max $3.73. ROI 42.7%. sentiment BULLISH.
The forecast shows bullish sentiment in several years (2027, 2028, 2029, 2033–2035, 2040, 2050) with averages rising to $4.38 by 2050 and ROI up to 190.2%. However, the outlook notes variability and not guaranteed results; the asset carries notable volatility (annualized volatility 200%).
Yes. In the forecast, the max prices show above $5 in 2033 ($5.51), 2034 ($5.41), and 2035 ($5.15), plus in later years such as 2040 ($8.03) and 2050 ($10.08).
min $1.55, avg $2.13, max $3.16. ROI 40.9%. sentiment BULLISH.
Current price $1.51; Market cap $5.52M.
Co-Diagnostics, Inc. Community Discussion
0Share your Co-Diagnostics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.